The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens. However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for the first two to five products to become available in about 10 years.